Vaglio Joseph C, Ommen Steve R, Nishimura Rick A, Tajik A Jamil, Gersh Bernard J
Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN, USA.
Am Heart J. 2008 Aug;156(2):342-7. doi: 10.1016/j.ahj.2008.04.002. Epub 2008 Jun 6.
The purpose of this article is to describe the demographic and clinical features of patients with hypertrophic cardiomyopathy (HCM) and latent obstruction, with an emphasis on identifying factors associated with disease progression and survival. The presence of a resting left ventricular outflow obstruction in patients with HCM has been well described and is associated with increased symptoms and adverse long-term outcomes. However, less is known about patients with latent obstruction.
Four hundred fifteen patients with echocardiographic or catheterization findings of latent obstruction, defined as a left ventricular outflow pressure gradient <30 mm Hg at rest, which increases to > or =30 mm Hg with provocation, were identified and included in the study group.
The mean age was 55.0 +/- 17.9, and 226 (54.6%) patients were male. There were 330 (79.5%) patients with New York Heart Association (NYHA) functional class I and II at baseline. Fifty-nine (17.9%) of these patients had symptom progression requiring septal reduction therapy. Eighty-five patients had severe symptoms (NYHA functional class III and IV) at baseline, and 23 (27.1%) underwent septal reduction. Overall survival at 1, 5, and 10 years was 98%, 91%, and 81%, respectively. Survival among patients after undergoing invasive relief of outflow obstruction was equivalent to the general US population.
Latent obstruction in HCM is an important pathophysiologic entity and may cause heart failure symptoms. One-third of patients in this referral series required invasive therapy for relief of symptoms. The evaluation of HCM patients with resting outflow tract gradients <30 mm Hg must include provocative maneuvers to identify this substantial subset of patients, preferably by physiologic exercise.
本文旨在描述肥厚型心肌病(HCM)合并潜在梗阻患者的人口统计学和临床特征,重点是确定与疾病进展和生存相关的因素。HCM患者静息时左心室流出道梗阻的情况已有充分描述,且与症状加重和不良长期预后相关。然而,对于潜在梗阻患者的了解较少。
通过超声心动图或心导管检查发现潜在梗阻(定义为静息时左心室流出道压力阶差<30mmHg,激发后压力阶差≥30mmHg)的415例患者被纳入研究组。
平均年龄为55.0±17.9岁,226例(54.6%)为男性。基线时,330例(79.5%)患者纽约心脏协会(NYHA)心功能分级为I级和II级。其中59例(17.9%)患者症状进展,需要进行室间隔减容治疗。85例患者基线时出现严重症状(NYHA心功能分级为III级和IV级),23例(27.1%)接受了室间隔减容治疗。1年、5年和10年的总体生存率分别为98%、91%和81%。接受有创性解除流出道梗阻治疗的患者生存率与美国普通人群相当。
HCM中的潜在梗阻是一种重要的病理生理实体,可能导致心力衰竭症状。在这个转诊系列中,三分之一的患者需要进行有创治疗以缓解症状。对于静息流出道压力阶差<30mmHg的HCM患者的评估必须包括激发试验,以识别这一相当大比例的患者亚组,最好通过生理性运动来进行。